Therapy development for ALS: Lessons learned and path forward

Amyotrophic Lateral Sclerosis

Volumn 9, Issue 3, 2008, Pages 131-140

  Lanka, Veena ^a   Cudkowicz, Merit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Study design

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ARIMOCLOMOL; ARUNDIC ACID; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CEFTRIAXONE; CELECOXIB; CENTRAL NERVOUS SYSTEM AGENTS; CILIARY NEUROTROPHIC FACTOR; CREATINE; DEXTROMETHORPHAN; GABAPENTIN; KNS 760704; LAMOTRIGINE; LITHIUM; MINOCYCLINE; PLACEBO; RILUZOLE; SELEGILINE; SODIUM PHENYLBUTYRATE; SOMATOMEDIN C; TALAMPANEL; TCH 346; THYROTROPIN; TOPIRAMATE; TRO 19622; UBIDECARENONE; UNINDEXED DRUG; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DISEASE MARKER; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MAXIMUM TOLERATED DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 47249154380     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960802112819     Document Type: Review

References (112)

1. Andersen, PM, Borasio, GD, Dengler, R., Hardiman, O., Kollewe, K. Leigh, PN et al. (2007) Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotrophic Lateral Sclerosis., 8, pp. 195-213.
2. Lechtzin, N., Scott, Y., Busse, AM, Clawson, LL, Kimball, R. and Wiener, CM. (2007) Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotrophic Lateral Sclerosis., 8, pp. 185-188.
3. Bruijn, LI, Miller, TM and Cleveland, DW. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annual Review of Neuroscience., 27, p. 723.
4. Bruijn, LI and Cleveland, DW. (1996) Mechanisms of selective motor neuron death in ALS: Insights from transgenic mouse models of motor neuron disease. Neuropathology Applied Neurobiology., 22, pp. 373-387.
5. Fornai, F., Longone, P., Ferrucci, M., Lenzi, P., Isidoro, C. Ruggieri, S. et al. (2008) Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium. Autophagy, 4
6. Lil, L., Zhang, X. and Le, W. (2008) Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy, 4, pp. 290-293.
7. MacGowan, DJ, Scelsa, SN, Imperato, TE, Liu, KN, Baron, P. and Polsky, B. (2007) A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology., 68, pp. 1944-1946.
8. Steele, AJ, Al-Chalabi, A., Ferrante, K., Cudkowicz, ME, Brown Jr, RH and Garson, JA. (2005) Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology., 64, pp. 454-458.
9. McCormick, AL, Brown Jr, RH, Cudkowicz, ME, Al-Chalabi, A. and Garson, JA. (2008) Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology., 70, pp. 278-283.
10. Rosen, DR, Siddique, T., Patterson, D., Figlewicz, DA, Sapp, P. Hentati, A. et al. (1993) Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature., 362, pp. 59-62.
11. Ralph, GS, Radcliffe, PA, Day, DM, Carthy, JM, Leroux, MA Lee, DCP et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Medicine., 11, pp. 429-433.
12. Xia, X., Zhou, H., Huang, Y. and Xu, Z. (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiology of Disease., 23, pp. 578-586.
13. Hadano, S., Hand, C., Osuga, H., Yanagisawa, Y., Otomo, A. Devon, R. et al. (2001) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis. Nat Genet., 29, pp. 166-173.
14. Puls, I., Jonnakuty, C., LaMonte, B., Holzbaur, E., Tokito, M. Mann, E. et al. (2003) Mutant dynactin in motor neuron disease. Nature Genetics., 33, pp. 455-456.
15. Chen, Y-Z, Hashemi, SH, Anderson, SK, Huang, Y., Moreira, M-C Lynch, DR et al. (2006) Senataxin, the yeast Sen1p orthologue: Characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiology of Disease., 23, pp. 97-108.
16. Sreedharan, J., Blair, IP, Tripathi, VB, Hu, X., Vance, C. Rogelj, B. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science
17. Gitcho, MA, Baloh, RH, Chakraverty, S., Mayo, K., Norton, JB Levitch, D. et al. (2008) TDP-43 A315T mutation in familial motor neuron disease. Annals of Neurology, 9999
18. Gurney, ME, Pu, H., Chiu, AY, Dal Canto, MC, Polchow, CY Alexander, DD et al. (1994) Motor neuron degeneration in mice that express a human Cu/ Zn superoxide dismutase mutation. Science., 264, pp. 1772-1775.
19. Kennel, P., Revah, F., Bohme, GA, Bejuit, R., Gallix, P. Stutzmann, J-M et al. (2000) Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci., 180, pp. 55-61.
20. Amyotrophic Lateral Sclerosis/Riluzole Study Group, II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, PN and Guillet, P. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. The Lancet., 347, pp. 1425-1431.
21. Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M. Manca, ML et al. (2008) Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences
22. Shefner, JM, Cudkowicz, ME, Schoenfeld, D., Conrad, T., Taft, J. Chilton, M. et al. (2004) A clinical trial of creatine in ALS. Neurology., 63, pp. 1656-1661.
23. Gordon, PH, Moore, DH, Florence, JM, Verheijde, JL, Spitalny, GM Doorish, C. et al. (2007) Results of the phase III randomized controlled trial of minocycline in ALS. Neurology., 68, p. A90.
24. Cudkowicz, M., Shefner, J., Schoenfeld, D., Zhang, H., Andreasson, K. Rothstein, J. et al. (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology., 60, pp. 22-31.
25. Miller, R., Moore, DH, Young, L. and Group, WS. (1996) Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology., 47, pp. 1383-1388.
26. Cudkowicz, M., Shefner, J., Schoenfeld, D., Brown, RJ, Johnson, H. Qureshi, M. et al. (2003) A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology., 61, pp. 456-464.
27. Desnuelle, C., Dib, M., Garrel, C. and Favier, A. (2001) A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders., 2, pp. 9-18.
28. Klivenyi, P., Ferrante, R., Matthew, R., Bogdanov, M., Klein, A. Mueller, G. et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of ALS. Nature Medicine., 5, pp. 347-350.
29. Zhu, S., Stavrovskaya, IG, Drozda, M., Kim, Ona, V. Li, M. et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature., 417, pp. 74-78.
30. Cudkowicz, ME, Shefner, JM, Schoenfeld, DA, Brown, RHJr, Johnson, H. Qureshi, M. et al. (2003) A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology., 61, pp. 456-464.
31. Drachman, D., Frank, K., Dykes-Hoberg, M., Teismann, P., Almer, G. Przedborski, S. et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Annals of Neurology., 52, pp. 771-778.
32. Alexander, GM, Erwin, KL, Byers, N., Deitch, JS, Augelli, BJ Blankenhorn, EP et al. (2004) Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Molecular Brain Research., 130, pp. 7-15.
33. Scott, S., Kranz, JE, Cole, J., Lincecum, JM, Thompson, K. Kelly, N. et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis., 9, pp. 4-15.
34. Gordon, PH, Moore, DH, Gelinas, DF, Qualls, C., Meister, ME Werner, J. et al. (2004) Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology., 62, pp. 1845-1847.
35. Bender, A., Koch, W., Elstner, M., Schombacher, Y., Bender, J. Moeschl, M. et al. (2006) Creatine supplementation in Parkinson's disease: A placebo-controlled randomized pilot trial. Neurology., 67, pp. 1262-1264.
36. Tabrizi, SJ, Blamire, AM, Manners, DN, Rajagopalan, B., Styles, P. Schapira, AHV et al. (2005) High-dose creatine therapy for Huntington's disease: A two-year clinical and MRS study. Neurology., 64, pp. 1655-1656.
37. Ryu, H., Smith, K., Camelo, SI, Carreras, I., Lee, J. Iglesias, AH et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry., 93, pp. 1087-1098.
38. Cudkowicz, ME, Andres, PL, Choudry, R., MacDonald, SA, Zhang, H. Schoenfeld, D. et al. (2007) Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS. Neurology, 68, p. A90.
39. Ranganathan, S., Jordan, K., Sathanoonri, R., Henry, S., Wood, P. Urbinelli, L. et al. (2003) Identification of ALS specific biomarkers by protein profiling of cerebral spinal fluid. ALS and Motor Neuron Disease., 4, p. 12.
40. Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. and Andersen, PM. (2007) Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. European Journal of Neurology., 14, pp. 1329-1333.
41. Bruijn, LI, Miller, TM and Cleveland, DW. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci., 27, pp. 723-749.
42. Groeneveld, GJ, Veldink, JH, van der Tweel, I., Kalmijn, S., Beijer, C. de Visser, M. et al. (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Annals of Neurology., 53, pp. 437-445.
43. Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A. Arbing, R. et al. (2006) A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology., 66, pp. 660-663.
44. Swartz, A SJ, Yu, H., Thornell, B., Sherman, A. and Cudkowicz, M. (2007) Design and implementation of a multi-phase, adaptive-design clinical trial for subjects with ALS. Amyotrophic Lateral Sclerosis., 8, pp. 142-143.
45. Schoenfeld, DA and Cudkowicz, M. (2008) Design of phase II ALS clinical trials. Amyotrophic Lateral Sclerosis., 9, pp. 16-23.
46. Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V. Mitsumoto, H. et al. (2007) Phase II/III randomized trial of TCH346 in patients with ALS. Neurology., 69, pp. 776-784.
47. Meininger, V., Bensimon, G., Bradley, WG, Brooks, BR, Douillet, P. Eisen, AA et al. (2004) Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord., 5, pp. 107-117.
48. Meininger, V. (2005) Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?. Neurodegenerative Diseases., 2, pp. 208-214.
49. Piepers, S., van den Berg, J-P, Kalmijn, S., van ver Pol, WL, Wokke, JHJ Lindeman, E. et al. (2006) Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: A review of the literature. Amyotrophic Lateral Sclerosis., 7, pp. 195-200.
50. Mazzini, L., Corra, T., Zaccala, M., Mora, G., Del Piano, M and Galante, M. (1995) Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry., 242, pp. 695-698.
51. Bensimon, G., Lacomblez, L., Meininger, V. and The ALS Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med, 330, pp. 585-591.
52. Miller, RG, Moore, DH, Gelinas, DF, Dronsky, B., Mendoza, M. Barohn, R. et al. (2001) Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology., 56, pp. 843-848.
53. Eisen, A., Stewart, H., Schulzer, M. and Cameron, D. (1993) Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine. The Canadian Journal of Neurological Sciences., 20, pp. 297-301.
54. Ryberg, H., Askmark, H. and Persson, LI. (2003) A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurologica Scandinavica., 108, pp. 1-8.
55. Gredal, O., Werdelin, L., Bak, S., Christensen, PB, Boysen, G. Kristensen, MO et al. (1997) A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica., 96, pp. 8-13.
56. ALS CNTF Treatment Study Group (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurol, 46, pp. 1244-1249.
57. Miller, R., Petajan, J., Bryan, W., Armon, C., Barohn, R. Goodpasture, J. et al. (1996) A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol., 39, pp. 256-260.
58. Borasio, GD, Robberecht, W., Leigh, PN, Emile, J., Guiloff, RJ Jerusalem, F. et al. (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology., 2, pp. 583-586.
59. The BDNF Study Group (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology, 52, pp. 1427-1433.
60. Munsat, T., Taft, J., Jackson, I., Andres, P., Hollander, D. Skerry, L. et al. (1992) Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system. Neurol., 42, pp. 1049-1053.
61. Brooke, MH, Florence, JM, Heller, SL, Kaiser, KK, Phillips, D. Gruber, A. et al. (1986) Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology., 36, pp. 146-151.
62. Graf, M., Ecker, D., Horowski, R., Kramer, B., Riederer, P. Gerlach, M. et al. (2005) High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. Journal of Neural Transmission., 112, pp. 649-660.
63. Louwerse, ES, Weverling, GJ, Bossuyt, PM, Meyjes, FE and de Jong, JM. (1995) Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol., 52, pp. 559-564.
64. Lange, D., Peregrine, L., Murphy, M., Diamond, B., Appel, V. Lai, E. et al. (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol., 55, pp. 93-96.
65. Ferrante, KL, Shefner, J., Zhang, H., Betensky, R., O'Brien, M. Yu, H. et al. (2005) Tolerance of high-dose (3000 mg/day) coenzyme Q10 in ALS. Neurology., 65, pp. 1834-1836.
66. Shefner, JM, Cudkowicz, ME, Schoenfeld, D., Conrad, T., Taft, J. Chilton, M. et al. (2004) A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology., 63, pp. 1656-1661.
67. The Italian ALS Study Group (1993) Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure?. Neurology, 43, pp. 2466-2470.
68. Tandan, R., Bromberg, MB, Forshew, D., Fries, TJ, Badger, GJ Carpenter, J. et al. (1996) A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology., 47, pp. 1220-1226.
69. Miller, RG, Shepherd, R., Dao, H., Khramstov, A., Mendoza, M. Graves, J. et al. (1996) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscular Disorders., 6, pp. 101-104.
70. Miller, RG, Smith, SA, Murphy, JR, Brinkmann, JR, Graves, J. Mendoza, M. et al. (1996) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle & Nerve., 19, pp. 511-515.
71. Meininger, V., Asselain, B., Guillet, P., Leigh, PN, Ludolph, A. Lacomblez, L. et al. (2006) Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial. Neurology., 66, pp. 88-92.
72. Gordon, PH, Moore, DH, Miller, RG, Florence, JM, Verheijde, JL Doorish, C. et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. The Lancet Neurology., 6, pp. 1045-1053.
73. Gourie-Devi, M., Nalini, A. and Subbakrishna, DK. (1997) Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J Neurol Sci., 150, pp. 167-172.
74. Bradley, WG, Hedlund, W., Cooper, C., Desousa, GJ, Gabbai, A. Mora, JS et al. (1984) A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurol, 34
75. Harrington, H., Hallett, M. and Tyler, HR. (1984) Ganglioside therapy for amyotrophic lateral sclerosis: A double-blind controlled trial. Neurology., 34, pp. 1083-1085.
76. Beghi, E., Chio, A., Inghilleri, M., Mazzini, L., Micheli, A. Mora, G. et al. (2000) A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology., 54, p. 469.
77. Chili, A., Cucatto, A., Terreni, A. and Schiffer, D. (1998) Reduced glutathione in amyotrophic lateral sclerosis: An open, cross-over, randomized trial. The Italian Journal of Neurological Sciences., 19, pp. 363-366.
78. Rutkove, SB, Parker, RA, Nardin, RA, Connolly, CE, Felice, KJ and Raynor, EM. (2002) A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology., 58, pp. 1081-1087.
79. Brooks, B. Tamoxifen phase II dose-escalation clinical trial in ALS: study design and safety results in first 50 patients. 14th International Symposium on ALS/MND
80. Beck, M., Karch, C., Wiese, S. and Sendtner, M. (2001) Motor neuron cell death and neurotrophic factors: Basic models for development of new therapeutic strategies in ALS. Amyotrophic Lateral Scler Other Motor Neuron Disord., 2, pp. 55-68.
81. Ghadge, GD, Wang, L., Sharma, K., Monti, AL, Bindokas, V. Stevens, FJ et al. (2006) Truncated wild-type SOD1 and FALS-linked mutant SOD1 cause neural cell death in the chick embryo spinal cord. Neurobiology of Disease., 21, pp. 194-205.
82. Silani, V., Braga, M., Ciammola, A., Cardin, V. and Scarlato, G. (2000) Motor neurons in culture as a model to study ALS. Journal of Neurology., 247, p. 36.
83. Matyja, E., Taraszewska, A., Naganska, E., Rafalowska, J. and Gebarowska, J. (2005) Astroglial alterations in amyotrophic lateral sclerosis (ALS) model of slow glutamate excitotoxicity in vitro. Folia Neuropathology., 43, pp. 7-13.
84. Di Giorgio, FP, Carrasco, MA, Siao, MC, Maniatis, T. and Eggan, K. (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci., 10, pp. 608-614.
85. Virgo, L., Dekkers, J., Mentis, GZ, Navarrete, R. and de Belleroche, J. (2000) Changes in expression of NMDA receptor subunits in the rat lumbar spinal cord following neonatal nerve injury. Neuropathology & Applied Neurobiology., 26, pp. 258-272.
86. Avossa, D., Grandolfo, M., Mazzarol, F., Zatta, M. and Ballerini, L. (2006) Early signs of motor neuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice. Neuroscience., 138, pp. 1179-1194.
87. Olivieri, G., Baysang, G., Meier, F., Muller-Spahn, F., Stahelin, HB Brockhaus, M. et al. (2001) N-Acetyl-l-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: Effects on beta-amyloid secretion and tau phosphorylation. Journal of Neurochemistry., 76, pp. 224-233.
88. Park, K-S, Kim, H-J, Choi, W-J, Kim, M. and Lee, K-W. (2004) Detection method of the adjacent motor neuronal death in an invitro coculture model of familial ALS-associated Cu/Zn superoxide dismutase. Biotechnology Letters., 26, pp. 1201-1205.
89. Liu, R., Narla, RK, Kurinov, I., Li, B. and Uckun, FM. (1999) Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. Radiation Research., 151, pp. 133-141.
90. Haenggeli, C. and Kato, AC. (2002) Differential vulnerability of cranial motor neurons in mouse models with motor neuron degeneration. Neuroscience Letters., 335, pp. 39-43.
91. Doble, A. and Kennel, P. (2000) Animal models of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron Disord., 1, pp. 301-312.
92. Nagai, M., Aoki, M., Miyoshi, I., Kato, M., Pasinelli, P. Kasai, N. et al. (2001) Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: Associated mutations develop motor neuron disease. J Neurosci., 23, pp. 9246-9254.
93. Watabe, K. (2007) Proximal axonal injuries as experimental models for adult motor neuron degeneration. Brain Nerve., 59, pp. 1179-1186.
94. LaMonte, BH, Wallace, KE, Holloway, BA, Shelly, SS, Ascano, J. Tokito, M. et al. (2002) Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron., 34, pp. 715-727.
95. Kwak, S. and Nakamura, R. (1995) Acute and late neurotoxicity in the rat spinal cord in vivo induced by glutamate receptor agonists. J Neurol Sci., 129, pp. 99-103.
96. Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D. Brusselmans, K. et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet., 28, pp. 131-138.
97. Rockenstein, E., Crews, L. and Masliah, E. (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Advanced Drug Delivery Reviews., 59, pp. 1093-1102.
98. Shulman, JM, Shulman, LM, Weiner, WJ and Feany, MB. (2003) From fruit fly to bedside: Translating lessons from Drosophila models of neurodegenerative disease., 16, pp. 443-449.
99. Cork, LC, Kitt, CA, Struble, RG, Griffin, JW and Price, DL. (1987) Animal models of degenerative neurological disease. Progress in Clinical and Biological Research., 229, pp. 241-269.
100. Zoccolella, S., Simone, IL, Lamberti, P., Samarelli, V., Tortelli, R. Serlenga, L. et al. (2008) Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology., 70, pp. 222-225.
101. Demestre, M., Parkin-Smith, G., Petzold, A. and Pullen, AH. (2005) The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. Journal of Neuroimmunology., 159, pp. 146-154.
102. Houi, K., Kobayashi, T., Kato, S., Mochio, S. and Inoue, K. (2002) Increased plasma TGF-1 in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica., 106, pp. 299-301.
103. Ilzecka, J. (2006) Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica., 114, pp. 205-209.
104. Pasinetti, GM, Ungar, LH, Lange, DJ, Yemul, S., Deng, H. Yuan, X. et al. (2006) Identification of potential CSF biomarkers in ALS. Neurology., 66, pp. 1218-1222.
105. Tsuboi, Y. and Yamada, T. (1994) Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry., 57, pp. 859-861.
106. Sekizawa, T., Openshaw, H., Ohbo, K., Sugamura, K., Itoyama, Y. and Niland, JC. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: Immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci., 154, pp. 194-199.
107. Nagata, T., Nagano, I., Shiote, M., Narai, H., Murakami, T. Hayashi, T. et al. (2007) Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurological Research., 29, pp. 772-776.
108. Baron, P., Bussini, S., Cardin, V., Corbo, M., Conti, G. Galimberti, D. et al. (2005) Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle & Nerve., 32, pp. 541-544.
109. Bogdanov, M., Brown, RH, Matson, W., Smart, R., Hayden, D. O'Donnell, H. et al. (2000) Increased oxidative damage to DNA in ALS patients. Free Radical Biology and Medicine., 29, pp. 652-658.
110. Simpson, EP, Henry, YK, Henkel, JS, Smith, RG and Appel, SH. (2004) Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology., 62, pp. 1758-1765.
111. Ilzecka, J. (2003) Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica., 108, pp. 125-129.
112. Pradat, PF, Bruneteau, G., Gonzalez de Aguilar, JL, Dupuis, L., Jokic, N. Salachas, F. et al. (2007) Muscle Nogo-a expression is a prognostic marker in lower motor neuron syndromes. Annals of Neurology., 62, pp. 15-20.